Hemostasis Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Hemostasis Diagnostics Market Report is Segmented by Product (Laboratory Analyzers [Automated Systems, and More], Point-Of-Care Testing Systems and More), Test (Activated Partial Thromboplastin Time, and More), Technology (Optical Detection, and More), End User (Hospitals, Diagnostic Laboratories, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Hemostasis Diagnostics Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Hemostasis Diagnostics Market with other markets in Healthcare Industry

Hemostasis Diagnostics Market Analysis by Mordor Intelligence

The hemostasis diagnostics market stood at USD 4.64 billion in 2025 and is on track to reach USD 5.88 billion by 2030, reflecting a 4.83% CAGR. Demand is buoyed by the rising prevalence of bleeding disorders, rapid uptake of viscoelastic testing platforms, and hospitals’ shift from centralized laboratories to point-of-care coagulation assessments. Automation, microfluidics, and artificial intelligence now underpin new analyzers that deliver reliable results from very small specimen volumes, a feature valued in neonatal, ECMO, and trauma settings. Regulatory tailwinds—including the FDA’s 2025 reclassification of viscoelastic systems into Class II—shorten market-entry timelines, while reimbursement headwinds and interoperability gaps temper the pace of adoption. Competitive intensity increases as suppliers integrate vertically, expand reagent portfolios, and bundle hardware with data-management solutions to secure multiyear laboratory contracts.

Key Report Takeaways

  • By product, laboratory analyzers led with 51.55% of the hemostasis diagnostics market share in 2024; point-of-care systems are projected to grow at an 8.25% CAGR to 2030.
  • By test, PT/INR dominated with 26.53% revenue share in 2024, while viscoelastic assays are forecast to advance at a 10.15% CAGR.
  • By technology, electrochemical and magnetic detection commanded 35.62% of the hemostasis diagnostics market size in 2024; microfluidics is expanding at a 10.52% CAGR through 2030.
  • By end user, hospitals accounted for 61.82% of 2024 revenue, whereas outpatient clinics are poised for 9.22% CAGR growth.
  • By geography, North America held 37.72% of 2024 revenue; Asia-Pacific is the fastest-growing region with an 8.22% CAGR.

Segment Analysis

By Product: Laboratory Analyzers Dominate, but POC Systems Accelerate

Laboratory analyzers generated 51.55% of 2024 revenue, anchoring the hemostasis diagnostics market with high-throughput capabilities and broad test menus. Automation, advanced reagent stability, and middleware connectivity help large core labs clear staffing bottlenecks while meeting tighter quality-control targets. Point-of-care (POC) systems, although a smaller base, are advancing at an 8.25% CAGR as emergency departments, catheterization labs, and ambulatory surgery centers seek rapid clotting profiles at the bedside. This trend reflects a deeper structural pivot toward decentralized care and value-based reimbursement, which rewards shorter length of stay and lower transfusion cost. The reagents and consumables stream linked to laboratory analyzers remains a resilient profit pool because kits require continual replacement to keep instruments compliant with IVDR and CLIA standards. Miniaturization is blurring category lines, with fingertip micro-sampling and cartridge-based assays allowing analyzers to migrate closer to patients without sacrificing throughput.

In parallel, the hemostasis diagnostics industry is witnessing a surge in hybrid workstations able to toggle between high-volume central-lab mode and stat-testing mode during peak OR hours. Suppliers are bundling instruments with closed-loop reagent contracts, laboratory information system connectivity, and on-site training to secure multiyear deals. Hospitals struggling with skilled-technologist vacancies lean heavily toward platforms that deliver automated calibration, real-time QC, and predictive maintenance alerts. These integrated offerings solidify vendor lock-in and extend the lifecycle of laboratory analyzers, even as POC systems rise.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Test: PT/INR Still Leads, Viscoelastic Assays Gain Ground

PT/INR retained 26.53% share of the hemostasis diagnostics market in 2024 because warfarin monitoring and surgical screening remain near-universal. Coumadin clinics and pre-op pathways rely on quick PT/INR readouts to adjust anticoagulant dosing and verify readiness for procedures. However, viscoelastic assays are sprinting ahead with a 10.15% CAGR. Surgeons and intensivists value whole-blood clot kinetics for targeted transfusion, a benefit conventional plasma-based tests cannot provide. D-dimer keeps its foothold in pulmonary embolism and deep-vein thrombosis workups, while fibrinogen tests gain traction for obstetric hemorrhage and trauma-induced coagulopathy risk stratification.

New test combinations, such as GFAP plus D-dimer for stroke triage, hint at multiplexed assay panels that could compress workups into a single sample. Even so, traditional aPTT remains indispensable for unfractionated heparin monitoring, preserving its place in the broader portfolio. As evidence mounts that viscoelastic-guided protocols save blood products and reduce ICU stays, tertiary centers add these assays to point-of-care carts, reshaping test-mix revenue within the hemostasis diagnostics market.

By Technology: Electrochemical Platforms Lead While Microfluidics Takes Off

Electrochemical and magnetic detection technologies captured 35.62% market share in 2024, favored for robust signal-to-noise ratios, adaptability to automation, and cost efficiency at scale. Optical detection retains wide use because legacy instruments are deeply embedded, yet faces gradual displacement as labs modernize. Microfluidics, posting a 10.52% CAGR, opens new frontiers by delivering comprehensive clotting profiles from microliter samples—a critical advance for neonates, ECMO patients, and field triage units. These lab-on-a-chip devices shorten analysis time to minutes without the need for centrifugation, aligning with emergency medicine workflows.

Mechanical detection remains relevant where direct clot-formation measurement is paramount, such as orthopedic surgery units monitoring antifibrinolytic therapy. Convergence is evident: next-generation analyzers fuse optical, mechanical, and electrochemical sensors with AI algorithms that flag aberrant patterns automatically. This integration reduces technician intervention and supports remote-monitoring models, strengthening the technology moat that established vendors hold in the hemostasis diagnostics market.

Market Share
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End User: Hospitals Remain Core, Outpatient Facilities Surge

Hospitals commanded 61.82% of 2024 revenue because complex surgeries, trauma services, and intensive care units rely on broad coagulation menus under one roof. In-house laboratories favor analyzer platforms that link directly with electronic medical records, safeguarding rapid clinician access to results. Yet outpatient clinics and ambulatory surgery centers form the fastest-growing channel at 9.22% CAGR as procedural care migrates away from inpatient facilities. Point-of-care devices—handheld or benchtop—let clinicians clear same-day cases without the delays of central lab routing.

Reference laboratories continue to service esoteric factor assays and rare platelet-function tests, while blood banks depend on coagulation screening for donor safety and component quality. Digital connectivity now connects all end-users to centralized data lakes, enabling benchmarking of transfusion ratios and reagent utilization across networks. Consequently, vendors tailor service contracts to each segment’s workflow, enlarging their total addressable footprint within the hemostasis diagnostics market.

Geography Analysis

North America led with 37.72% of 2024 revenue thanks to sophisticated hospital networks, early adoption of automated analyzers, and stable reimbursement for advanced diagnostics. The United States’ dense trauma centers and transplant programs generate a steady stream of viscoelastic test demand, while the FDA’s 2025 Class II ruling eases new-device onboarding[3]Food and Drug Administration, “Classification of the Coagulation System for the Measurement of Whole Blood Viscoelastic Properties in Perioperative Patients,” federalregister.gov. Canada mirrors U.S. trends but places greater emphasis on provincial bulk-purchase contracts that favor multi-analyte platforms. Mexico’s ongoing health-system reform drives centralized laboratory buildouts, opening incremental sales channels for mid-tier analyzers.

Asia-Pacific is the fastest-growing geography, advancing at an 8.22% CAGR. China’s volume-based procurement pressures pricing for reagents, yet massive procedure volumes sustain absolute growth. Japan’s aging demographic fuels demand for chronic anticoagulation monitoring, while its technologically adept hospitals rapidly integrate AI-enabled platelet imaging. India’s expansion of indigenous manufacturing—seen in Sysmex’s new facilities—lowers acquisition costs for public hospitals, broadening access to automated hemostasis panels. South Korea and Australia, each with robust trauma and cardiac-surgery programs, continue to install viscoelastic analyzers alongside existing laboratory workstations. These combined forces elevate Asia-Pacific’s share of the hemostasis diagnostics market year by year.

Europe maintains steady mid-single-digit gains amid stringent IVDR compliance. Germany and France adopt microfluidic cartridges swiftly in high-acuity centers, whereas the United Kingdom accelerates point-of-care deployment through National Health Service modernization funds. Southern European nations invest selectively, prioritizing transfusion-sparing technologies to curb blood-product expenditures. The Middle East and Africa trail but show pockets of momentum in Gulf Cooperation Council states where new tertiary hospitals specify centralized coagulation labs from day one. Latin America’s growth rests largely on Brazil and Argentina, which are expanding trauma-care infrastructure and adopting viscoelastic testing in private hospital groups. Collectively, these regional narratives underscore varied but converging trajectories that keep the hemostasis diagnostics market on a positive global slope.

Growth Rate
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The hemostasis diagnostics market remains moderately fragmented, with leading suppliers pursuing vertical integration and platform consolidation to defend share. Abbott, Danaher, Roche, Sysmex, Siemens Healthineers, and Werfen deploy multi-year R&D pipelines, emphasizing automation, microfluidics, and digital connectivity. Thermo Fisher’s USD 2 billion U.S. innovation program underscores scale advantages that furnish smaller firms with OEM reagents while reinforcing its own production security. Werfen’s unification of subsidiaries streamlines brand architecture, reinforcing its focus on specialized coagulation and point-of-care lines.

Strategic acquisitions intensify. Werfen’s prior purchase of Accriva Diagnostics bolstered its POC catalog, while Merit Medical’s 2025 acquisition of Biolife extended into hemostatic wound-management adjuncts, bridging devices and diagnostics. bioMérieux’s USD 141.8 million buyout of SpinChip adds a 10-minute whole-blood immunoassay platform, signaling convergence between coagulation and infectious-disease testing in near-patient settings. Siemens Healthineers’ OEM pact with Sysmex extends a 25-year partnership, blending extensive reagent lines with next-generation hardware to counter newcomer microfluidic entrants.

Technology differentiation revolves around throughput, sample-volume efficiency, and informatics. Vendors now embed middleware that pushes QC alerts directly to mobile dashboards, shrinking downtime. Cloud-ready analyzers furnish anonymized datasets for algorithm training, an emergent value proposition for customers seeking predictive transfusion analytics. Start-ups working on nanoengineered biosensors or AI-driven imaging target white-space segments such as ultra-rapid thrombosis prediction and non-invasive clot visualization, forcing incumbents to accelerate their own digital roadmaps. As procurement moves to total-cost-of-ownership evaluations rather than instrument price alone, bundled reagent-service contracts and guaranteed uptime become decisive differentiators, shaping competitive contours within the hemostasis diagnostics market.

Hemostasis Diagnostics Industry Leaders

  1. Thermo Fisher Scientific, Inc.

  2. F. Hoffmann-La Roche Ltd

  3. Nihon Kohden Corporation

  4. Abbott Laboratories

  5. Siemens Healthineers

  6. *Disclaimer: Major Players sorted in no particular order
Hemostasis Diagnostics Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • May 2025: Merit Medical acquired hemostatic device maker Biolife for USD 120 million to broaden its vascular closure and hemostasis product suite.
  • January 2025: bioMérieux purchased SpinChip Diagnostics for USD 141.8 million, adding a rapid whole-blood immunoassay platform capable of 10-minute results.

Table of Contents for Hemostasis Diagnostics Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Incidences Of Bleeding Disorders
    • 4.2.2 Technological Advancements In Coagulation Testing
    • 4.2.3 Rising Adoption Of Automated Hemostasis Equipment
    • 4.2.4 Adoption Of Viscoelastic Testing (TEG/ROTEM) For Transfusion Management
    • 4.2.5 Microfluidic Point-Of-Care (POC) Assays Enabling Decentralized Testing
    • 4.2.6 Low-Volume Monitoring Demand In ECMO & Critical Care
  • 4.3 Market Restraints
    • 4.3.1 Lack Of Awareness In Developing Economies
    • 4.3.2 Stringent Regulatory Approval Processes
    • 4.3.3 Reimbursement Gaps For Advanced POC Devices
    • 4.3.4 Data-Interoperability Issues With LIS / HIS Integration
  • 4.4 Technological Outlook
  • 4.5 Porter's Five Forces
    • 4.5.1 Threat of New Entrants
    • 4.5.2 Bargaining Power of Buyers/Consumers
    • 4.5.3 Bargaining Power of Suppliers
    • 4.5.4 Threat of Substitute Products
    • 4.5.5 Intensity of Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Product
    • 5.1.1 Laboratory Analyzers
    • 5.1.1.1 Automated Systems
    • 5.1.1.2 Semi-automated Systems
    • 5.1.1.3 Manual Systems
    • 5.1.2 Point-of-Care Testing Systems
    • 5.1.3 Reagents & Consumables
  • 5.2 By Test
    • 5.2.1 Activated Partial Thromboplastin Time (aPTT)
    • 5.2.2 Prothrombin Time (PT/INR)
    • 5.2.3 D-Dimer
    • 5.2.4 Fibrinogen
    • 5.2.5 Thrombin Time & Clotting-Factor Assays
    • 5.2.6 Viscoelastic Tests (TEG, ROTEM)
  • 5.3 By Technology
    • 5.3.1 Optical Detection
    • 5.3.2 Mechanical Detection
    • 5.3.3 Electrochemical & Magnetic Detection
    • 5.3.4 Microfluidics & Lab-on-Chip
  • 5.4 By End User
    • 5.4.1 Hospitals
    • 5.4.2 Diagnostic Laboratories
    • 5.4.3 Outpatient Clinics & Ambulatory Surgery Centers
    • 5.4.4 Blood Banks
  • 5.5 Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 South Korea
    • 5.5.3.5 Australia
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
    • 6.3.1 Abbott Laboratories
    • 6.3.2 Danaher Corp.
    • 6.3.3 F. Hoffmann-La Roche Ltd
    • 6.3.4 Grifols
    • 6.3.5 Werfen (Instrumentation Laboratory)
    • 6.3.6 Sysmex Corporation
    • 6.3.7 Siemens Healthineers
    • 6.3.8 Nihon Kohden Corporation
    • 6.3.9 HORIBA
    • 6.3.10 Bio-Rad Laboratories
    • 6.3.11 Thermo Fisher Scientific, Inc.
    • 6.3.12 Diagnostica Stago
    • 6.3.13 Helena Laboratories
    • 6.3.14 Haemonetics (HemoSonics)
    • 6.3.15 CSL Behring
    • 6.3.16 Baxter International
    • 6.3.17 Becton, Dickinson & Co.
    • 6.3.18 Medtronic (ViscoStat)

7. Market Opportunities & Future Outlook

  • 7.1 White-space & Unmet-need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Hemostasis Diagnostics Market Report Scope

As per the scope of the report, hemostasis diagnostics are devices that help identify hemostatic defects that lead to excessive bleeding. Hemostasis is a mechanism followed by the body after getting injured. It slows down blood loss and stops blood flow. Hemostasis helps diagnose the actual cause of these disorders with history and helps in the treatment.

The hemostasis diagnostics market is segmented by product, test, end-use, and geography. By product, the market is segmented as laboratory analyzers and point-of-care testing systems. By test, the market is segmented into activated partial thromboplastin time, D-dimer test, fibrinogen test, prothrombin time (PT) test, and other tests. By end user, the market is segmented into hospitals, diagnostic centers, and other end users. The market is segmented by geography, such as North America, Europe, Asia Pacific, Middle East and Africa, and South America. The report also covers the market sizes and forecasts for the hemostasis diagnostics market in major countries across different regions. The report offers the market size in value terms in USD for all the abovementioned segments.

By Product Laboratory Analyzers Automated Systems
Semi-automated Systems
Manual Systems
Point-of-Care Testing Systems
Reagents & Consumables
By Test Activated Partial Thromboplastin Time (aPTT)
Prothrombin Time (PT/INR)
D-Dimer
Fibrinogen
Thrombin Time & Clotting-Factor Assays
Viscoelastic Tests (TEG, ROTEM)
By Technology Optical Detection
Mechanical Detection
Electrochemical & Magnetic Detection
Microfluidics & Lab-on-Chip
By End User Hospitals
Diagnostic Laboratories
Outpatient Clinics & Ambulatory Surgery Centers
Blood Banks
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Product
Laboratory Analyzers Automated Systems
Semi-automated Systems
Manual Systems
Point-of-Care Testing Systems
Reagents & Consumables
By Test
Activated Partial Thromboplastin Time (aPTT)
Prothrombin Time (PT/INR)
D-Dimer
Fibrinogen
Thrombin Time & Clotting-Factor Assays
Viscoelastic Tests (TEG, ROTEM)
By Technology
Optical Detection
Mechanical Detection
Electrochemical & Magnetic Detection
Microfluidics & Lab-on-Chip
By End User
Hospitals
Diagnostic Laboratories
Outpatient Clinics & Ambulatory Surgery Centers
Blood Banks
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the current size of the hemostasis diagnostics market?

The market generated USD 4.64 billion in 2025 and is expected to grow to USD 5.88 billion by 2030 at a 4.83% CAGR.

Which region is growing fastest?

Asia-Pacific is expanding at an 8.22% CAGR thanks to rising surgical volumes, broader healthcare access, and accelerating technology adoption.

Why are viscoelastic assays gaining popularity?

They provide real-time, whole-blood clot kinetics that guide targeted transfusion, reducing blood-product use and improving outcomes in trauma, cardiac surgery, and transplantation.

How are regulatory changes affecting the market?

The FDA’s 2025 Class II reclassification streamlines U.S. approvals, while Europe’s IVDR imposes stricter validation burdens, collectively shaping product launch timelines.

What role does automation play in market growth?

Automated analyzers boost throughput, reduce human error, and help labs meet tightened quality-control targets, making them indispensable amid workforce shortages.

Which product segment is expected to grow fastest?

Point-of-care testing systems are projected to rise at an 8.25% CAGR as care pathways shift toward outpatient and emergency settings requiring immediate coagulation results.

Page last updated on: June 20, 2025

Hemostasis Diagnostics Market Report Snapshots